KRAS and lung carcinoma: Using the next-generation targeted metabolomics method, Caiola et al. explored the metabolic differences between the lung cancer cells with KRAS mutation and the wild type non-mutated lung cancer cells, and it was found that the level of glutamine was significantly decreased in the lung cancer cells with KRAS mutation, and this finding can be used to distinguish this type of mutation [53].